Get Critical Health Info

Advocacy

FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Advocacy > Advocacy Issues

| More

Newsflash

11/8/17
FORCE, along with 60 other patient groups, is asking the Senate to preserve medical expense deductions in any forthcoming tax reform legislation.  

10/25/17
We joined over 100 Defense Health Research Consortium orgs in supporting DoD research funding. Learn more...

9/22/17
Check out this new video w/FORCE & 15 other cancer orgs representing patients, physicians, nurses, & social workers. Oppose Graham-Cassidy! See Video...

9/14/17
FORCE reps were in St. Louis today for an ICER hearing on the value and cost of PARP inhibitors for ovarian cancer patients.

Therapies & Drug Development

FORCE is at the forefront of research and development of therapies for the treatment or prevention of cancers in people affected hereditary cancer. Our organization is active in research advocacy, clinical trial recruitment, drug review and approval, etc. with partners including government agencies, academia and private industry. Our goal is to ensure access to a range of effective treatments for people of every stage and type of hereditary cancer.

Treatments & Therapies

Cancer Research Funding

Federal funding for cancer research has led to significant advances in cancer prevention, detection, diagnosis, treatment, and quality of life for patients. More than 14 million U.S. cancer survivors are alive today, largely because of the nation’s commitment to cancer research. The main sources of cancer research funding in the U.S. are the National Institutes of Health (NIH), which includes the National Cancer Institute (NCI), and the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP).

Treatments & Therapies

ICER Review of PARP Inhibitors for Ovarian Cancer

In July 2017, the Institute for Clinical and Economic Review (ICER) released a draft evidence report titled, “Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value.” FORCE has concerns about the report's conclusions as there are significant differences in the patient populations used for comparative data and gaps in the costs used for the value analysis. Additionally, the analysis design does not adequately represent the interests of patients, clinicians, or the hereditary cancer community. FORCE expressed these concerns via written comments and testified at the Midwest CEPAC meeting on September 14, 2017.

Treatments & Therapies

Cancer Moonshot

In his final State of the Union address in 2016, President Obama tasked Vice President Biden with heading up a new national effort, the Cancer Moonshot. The ultimate goal of Moonshot is to double the rate of progress—to make a decade's worth of advances in cancer prevention, diagnosis, treatment, and care in five years—to ultimately end cancer as we know it. FORCE is proud to be engaged in the Moonshot initiative via the ABOUT Network, the only cancer-focused patient-powered research network in PCORnet. 

Treatments & Therapies

FDA Approval of Lynparza: A Win for the HBOC Community

On December 19, 2014, the FDA announced approval of Lynparza (also known as olaparib) for women with BRCA mutations who have ovarian, fallopian tube or primary peritoneal cancer, and who have received three or more chemotherapy treatments. FORCE has been a strong advocate for PARP inhibitor research and targeted therapies for nearly a decade. This is the first FDA-approved PARP inhibitor, and it is a great win for the BRCA community. 

Treatments & Therapies

Oral Chemotherapy Offers New Treatment Option for Some Patients

As cancer treatments advance, more patients are taking oral chemotherapy. In fact, oral chemotherapy is now the standard of care for many types of cancer. Oral treatment also accounts for about a third of the oncology development pipeline. Importantly, many oral anti-cancer medications do not have IV or injected alternatives, and are the only option for some patients. FORCE is supporting the Cancer Drug Coverage Parity Act, a national legislative initiative which strives to create equal insurance coverage of patient administered and physician administered cancer treatments.

Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered